Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd Announced the Chinese Approval for a Rabies Drug

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc., (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis. Clinical results showed Orm...

Full "IntellAsia: Resources" article